Pfizer's Currency, Patent Pressures Boost Allergan Merger's Importance
This article was originally published in Scrip
Pfizer Inc.'s pending $160bn merger with Allergan PLC may be its best shot at significant revenue growth this year, since the company's 2015 revenue and earnings fell below 2014 totals due to foreign currency impacts and the loss of patent exclusivity for multiple products – factors that again could lead to flat growth during the current year, despite meaningful sales gains for certain products.
You may also be interested in...
Presentation of data at Alzheimer’s Association International Conference highlights failure of Pfizer’s 5HT6 antagonist PF-05212377, while still leaving room to hope for others in class like Lundbeck’s idalopirdine and Axovant’s RVT-101
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
The company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.